Development and Validation of an Abbreviated Version of the Expanded Prostate Cancer Index Composite Instrument for Measuring Health-related Quality of Life Among Prostate Cancer Survivors

Widespread implementation of health-related quality-of-life (HRQOL) measurement in prostate cancer practice and research requires concise instruments. With 50 questions, the full-length Expanded Prostate Cancer Index Composite (EPIC) is cumbersome to administer outside of studies focusing exclusivel...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Urology (Ridgewood, N.J.) Ročník 76; číslo 5; s. 1245 - 1250
Hlavní autoři: Szymanski, Konrad M., Wei, John T., Dunn, Rodney L., Sanda, Martin G.
Médium: Journal Article
Jazyk:angličtina
Vydáno: New York, NY Elsevier Inc 01.11.2010
Elsevier
Témata:
Biological and medical sciences
Gynecology. Andrology. Obstetrics
Health Status
Humans
Male
Male genital diseases
Medical sciences
Nephrology. Urinary tract diseases
Prostatectomy
Prostatic Neoplasms - radiotherapy
Prostatic Neoplasms - therapy
Quality of Life
Surveys and Questionnaires
Survivors
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Urology
Validation
Nephrology
Urinary system disease
Prostate disease
Survivor
Index
Malignant tumor
Health-Related Quality of Life
Urology
Measuring instrument
Development
Male genital diseases
Prostate cancer
Cancer
ISSN:0090-4295, 1527-9995, 1527-9995
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Widespread implementation of health-related quality-of-life (HRQOL) measurement in prostate cancer practice and research requires concise instruments. With 50 questions, the full-length Expanded Prostate Cancer Index Composite (EPIC) is cumbersome to administer outside of studies focusing exclusively on HRQOL. To facilitate HRQOL measurement in a broad range of prostate cancer research and practice settings, we developed and validated an abbreviated version of the EPIC. The 50 questions that constitute the full-length EPIC-50 were evaluated to identify the items suitable for elimination while retaining the ability to measure the 5 prostate cancer-specific HRQOL domains of the EPIC-50. The resulting abbreviated version (EPIC-26) was validated using question responses from 252 subjects who had undergone brachytherapy, external beam radiotherapy, or prostatectomy for prostate cancer. The EPIC-26 internal consistency was measured by Cronbach's α coefficient and reliability using test–retest correlation. Using the high item–scale correlations, clinically relevant content, and preservation of domain psychometrics, 26 items were retained in the EPIC-26 from the 50 questions in the full-length EPIC-50. A high correlation was observed between the EPIC-50 and EPIC-26 versions for the urinary incontinence, urinary irritation/obstruction, bowel, sexual, and vitality/hormonal domain scores (all r ≥0.96). The correlations between the different domains were low, confirming that EPIC-26 retained the ability to discern the 5 distinct HRQOL domains. The internal consistency and test–retest reliability for EPIC-26 (Cronbach's α ≥0.70 and r ≥0.69, respectively for all 5 HRQOL domains) supported its validity. EPIC-26 is a brief, valid, and reliable subjective measure of health quality among patients with prostate cancer and is suitable for measuring the HRQOL among patients undergoing treatment of early-stage prostate cancer.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0090-4295
1527-9995
1527-9995
DOI:10.1016/j.urology.2010.01.027